BACKGROUND/AIM: STK11/LKB1 mutation has been suggested as a poorly responding candidate biomarker of the anti-programmed cell death-1 (PD-1) antibody; however, the association between STK11/LKB1 expression and the effects of anti-PD-1 antibodies is uncertain. The aim of the study was to correlate the efficacy of pembrolizumab monotherapy and STK11/LKB1 expression in untreated patients with non-small-cell lung carcinoma (NSCLC) and high PD-ligand 1 expression. PATIENTS AND METHODS: From February 2017 to January 2020, we retrospectively analyzed 30 previously untreated patients with NSCLC and a tumor proportion score (TPS) ≥50% treated with pembrolizumab monotherapy. STK11/LKB1 expression in tumor tissue was evaluated by immunohistochemistry. RESULTS: Twenty-three (76.7%) of the 30 patients were classified with low-STK11/LKB1 expression. The median progression-free survival and overall survival of patients with low-STK11/LKB1 expression was shorter than those with high-STK11/LKB1 expression, although the results were not statistically significant. The disease progression rate for the low-STK11/LKB1 group was higher than that of the high-STK11/LKB1 group. CONCLUSION: STK11/LKB1 expression, as measured by immunohistochemistry, could be a useful biomarker associated with the efficacy of pembrolizumab monotherapy for patients with NSCLC and a TPS ≥50%. Copyright
BACKGROUND/AIM: STK11/LKB1 mutation has been suggested as a poorly responding candidate biomarker of the anti-programmed cell death-1 (PD-1) antibody; however, the association between STK11/LKB1 expression and the effects of anti-PD-1 antibodies is uncertain. The aim of the study was to correlate the efficacy of pembrolizumab monotherapy and STK11/LKB1 expression in untreated patients with non-small-cell lung carcinoma (NSCLC) and high PD-ligand 1 expression. PATIENTS AND METHODS: From February 2017 to January 2020, we retrospectively analyzed 30 previously untreated patients with NSCLC and a tumor proportion score (TPS) ≥50% treated with pembrolizumab monotherapy. STK11/LKB1 expression in tumor tissue was evaluated by immunohistochemistry. RESULTS: Twenty-three (76.7%) of the 30 patients were classified with low-STK11/LKB1 expression. The median progression-free survival and overall survival of patients with low-STK11/LKB1 expression was shorter than those with high-STK11/LKB1 expression, although the results were not statistically significant. The disease progression rate for the low-STK11/LKB1 group was higher than that of the high-STK11/LKB1 group. CONCLUSION:STK11/LKB1 expression, as measured by immunohistochemistry, could be a useful biomarker associated with the efficacy of pembrolizumab monotherapy for patients with NSCLC and a TPS ≥50%. Copyright
Authors: Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer Journal: N Engl J Med Date: 2016-10-08 Impact factor: 91.245
Authors: Fikret Sahin; Anirban Maitra; Pedram Argani; Norihiro Sato; Naoki Maehara; Elizabeth Montgomery; Michael Goggins; Ralph H Hruban; Gloria H Su Journal: Mod Pathol Date: 2003-07 Impact factor: 7.842
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Ferdinandos Skoulidis; Michael E Goldberg; Danielle M Greenawalt; Matthew D Hellmann; Mark M Awad; Justin F Gainor; Alexa B Schrock; Ryan J Hartmaier; Sally E Trabucco; Laurie Gay; Siraj M Ali; Julia A Elvin; Gaurav Singal; Jeffrey S Ross; David Fabrizio; Peter M Szabo; Han Chang; Ariella Sasson; Sujaya Srinivasan; Stefan Kirov; Joseph Szustakowski; Patrik Vitazka; Robin Edwards; Jose A Bufill; Neelesh Sharma; Sai-Hong I Ou; Nir Peled; David R Spigel; Hira Rizvi; Elizabeth Jimenez Aguilar; Brett W Carter; Jeremy Erasmus; Darragh F Halpenny; Andrew J Plodkowski; Niamh M Long; Mizuki Nishino; Warren L Denning; Ana Galan-Cobo; Haifa Hamdi; Taghreed Hirz; Pan Tong; Jing Wang; Jaime Rodriguez-Canales; Pamela A Villalobos; Edwin R Parra; Neda Kalhor; Lynette M Sholl; Jennifer L Sauter; Achim A Jungbluth; Mari Mino-Kenudson; Roxana Azimi; Yasir Y Elamin; Jianjun Zhang; Giulia C Leonardi; Fei Jiang; Kwok-Kin Wong; J Jack Lee; Vassiliki A Papadimitrakopoulou; Ignacio I Wistuba; Vincent A Miller; Garrett M Frampton; Jedd D Wolchok; Alice T Shaw; Pasi A Jänne; Philip J Stephens; Charles M Rudin; William J Geese; Lee A Albacker; John V Heymach Journal: Cancer Discov Date: 2018-05-17 Impact factor: 39.397
Authors: Ni Zhao; Matthew D Wilkerson; Usman Shah; Xiaoying Yin; Anyou Wang; Michele C Hayward; Patrick Roberts; Carrie B Lee; Alden M Parsons; Leigh B Thorne; Benjamin E Haithcock; Juneko E Grilley-Olson; Thomas E Stinchcombe; William K Funkhouser; Kwok-Kin Wong; Norman E Sharpless; D Neil Hayes Journal: Lung Cancer Date: 2014-08-30 Impact factor: 5.705
Authors: José F Carrillo; Christian Cruz-Romero; Alejandro Avilés-Salas; Liliana C Carrillo; Margarita C Ramírez-Ortega; Roberto Herrera-Goepfert; Rafael Vázquez-Romo; Gabriela Figueroa-González; Javier I Altamirano-García; Luis F Oñate-Ocaña Journal: Ann Surg Oncol Date: 2022-03-23 Impact factor: 5.344